Results 181 to 190 of about 20,052 (248)

Current Insights and Future Directions on the Role of GLP-1 Receptor Agonists in Chronic Kidney Disease. [PDF]

Int J Nephrol Renovasc Dis
Rajan K, Jutley AK, Holliday MW, Navaneethan SD.   +3 more
europepmc   +1 more source

Current Trends in the Epidemiology of Obesity and the Association Between Obesity and Metabolic Liver Disease (MASLD/MASH)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Excess adiposity and obesity are increasingly prevalent, with incidence rising in many parts of the world; both trigger a state of metabo‐inflammation in adipose tissue, creating a systemic milieu characterised by insulin resistance and pro‐inflammatory and fibrogenic states. Along with systemic inflammatory cues, perturbations in systemic and
Mirjana Grocic, Madison Nguyen, Arun J. Sanyal   +2 more
wiley   +1 more source

Psychiatric Adverse Events and Administration Challenges Associated with GLP-1 Receptor Agonists for Weight Loss: A Real-World Analysis. [PDF]

Pharmaceuticals (Basel)
Hindi A, Mekkawy M, Shokr H.
europepmc   +1 more source

Association of GLP‐1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation and the risk of hepatic decompensation compared with dipeptidyl peptidase 4 inhibitors (DPP4is) in a racially and ethnically diverse cohort of adults with Type 2 diabetes.
Inyoung Hwang, Yun Kim, Sang Won Lee
wiley   +1 more source

Real-world effectiveness, safety, and quality of life of biosynthetic semaglutide in Pakistani adults with type 2 diabetes mellitus: a study protocol. [PDF]

J Pharm Policy Pract
Daoud Butt M, Hussain A, Ong SC.
europepmc   +1 more source

Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Treatment options for adolescents with obesity are limited, and some may benefit from lower maintenance doses of semaglutide. This study used model‐informed drug development (MIDD) to evaluate whether a 1.7‐mg maintenance dose provides comparable exposure, tolerability and BMI effects in adolescents versus adults and versus the 2.4‐mg ...
Anders Strathe, Eric M. Bomberg, Garrit Jensch, Jonas Kildegaard, Nina M. Harder‐Lauridsen, Daniel Weghuber, Rune Viig Overgaard   +6 more
wiley   +1 more source

GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials. [PDF]

Medicine (Baltimore)
Ahmad N, Alruwayyes A, Alarjani A, Tawhari A, Aldosri A, Alahmari A, Balaha M.   +6 more
europepmc   +1 more source

Association of Tirzepatide With Kidney Parameters in Participants With Obesity and Prediabetes From SURMOUNT‐1 Over 176 Weeks

Diabetes, Obesity and Metabolism, EarlyView.
Hiddo J. L. Heerspink, Daniel H. van Raalte, Katherine Tuttle, David Z. I. Cherney, Petter Bjornstad, Dachuang Cao, Georgios K. Dimitriadis, Bruno Linetzky, Irina Jouravskaya, Mathijs C. Bunck, Ryan Griffin, Claire Gerber   +11 more
wiley   +1 more source

Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real‐World: Results From the SCORE—Clinical ASCVD Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the association between semaglutide 2.4 mg and major adverse cardiovascular events (MACE) among adults with clinical atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity without diabetes in real‐world clinical practice.
Michael G. Nanna, Carlos Mena‐Hurtado, Victoria Divino, Zhenxiang Zhao, Yan Chen, Joanna Boland, Jinlin Song, Andrea Traina, Kerem Ozer, Filip K. Knop, Kim G. Smolderen   +10 more
wiley   +1 more source

Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes: a Danish nationwide cohort study. [PDF]

Hum Reprod Open
Hviid KVR, Banasik K, Mortensen LH, Madsbad S, Strandberg-Larsen K, Geiker NRW, Westergaard D, Nielsen HS.   +7 more
europepmc   +1 more source